Simona Di Giulio

Dr. Simona Di Giulio

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Elisabetta CarataElisabetta Carata
Elisabetta Carata
MMMarco Muci
Marco Muci
SGSimona Di Giulio
Simona Di Giulio
SMStefania Mariano
Stefania Mariano
EPElisa Panzarini
Elisa Panzarini
Neuroinflammation is a common pathological feature of amyotrophic lateral sclerosis (ALS). Although scientific evidence to date does not allow defining neuroinflammation as an ALS trigger, its role in exacerbating motor neuron (MNs) degeneration and disease progression is attracting research interest. Activated CNS (Central Nervous System) glial cells, proinflammatory peripheral and infiltrated T lymphocytes and monocytes/macrophages, as well as the immunoreactive molecules they release, represent the active players for the role of immune dysregulation enhancing neuroinflammation. The crosstalk between the peripheral and CNS immune cells significantly correlates with the survival of ALS patients since the modification of peripheral macrophages can downregulate inflammation at the periphery along the nerves and in the CNS. As putative vehicles for misfolded protein and inflammatory mediators between cells, extracellular vesicles (EVs) have also drawn particular attention in the field of ALS. Both CNS and peripheral immune cells release EVs, which are able to modulate the behavior of neighboring recipient cells; unfortunately, the mechanisms involved in EVs-mediated communication in neuroinflammation remain unclear. This review aims to synthesize the current literature regarding EV-mediated cell-to-cell communication in the brain under ALS, with a particular point of view on the role of peripheral macrophages in responding to inflammation to understand the biological process and exploit it for ALS management.

30 May 2023 in Applied Sciences
Verified
Journal Article
Open access
PDF file
SGSimona Di Giulio
Simona Di Giulio
Elisabetta CarataElisabetta Carata
Elisabetta Carata
SMStefania Mariano
Stefania Mariano
EPElisa Panzarini
Elisa Panzarini
Plant-derived extracellular vesicles (EVs) isolated from seeds, leaves, and fruits have shown a significant therapeutic potential for their anticancer, anti-inflammatory, and antioxidant properties. The ability to transport bioactive molecules and the low toxicity give EVs remarkable versatility in the field of nanomedicine for the development of drug delivery systems. Moreover, the physicochemical stability in gastric and intestinal fluids makes them the ideal candidate as nutritional carriers in oral formulations. It is well known that the consumption of antioxidant molecules from dietary plant sources, such as fruits and vegetables, can prevent pathologies caused by oxidative damage, including inflammatory and cardiovascular disease, neurodegeneration, aging, and cancer. EVs present in plant juices are receiving a lot of interest concerning their biological relevance in terms of their health benefits. EVs from food might be new components participating in body homeostasis, as they are in contact with the intestinal tract. This review aims to report and discuss the main biological properties and nutraceutical use of plant-derived EVs as promising therapeutic tools, with a focus on anti-oxidant effect and as a basis in developing new food-derived technology.

Verified
Journal Article
Open access
Elisabetta CarataElisabetta Carata
Elisabetta Carata
MMMarco Muci
Marco Muci
SGSimona Di Giulio
Simona Di Giulio
Tiziano Di GiulioTiziano Di Giulio
Tiziano Di Giulio
SMStefania Mariano
Stefania Mariano
EPElisa Panzarini
Elisa Panzarini
Amyotrophic lateral sclerosis (ALS) represents a neurodegenerative disorder characterized by the progressive loss of both upper and lower motor neurons, resulting in muscular atrophy and eventual paralysis. While much research has concentrated on investigating the impact of major mutations associated with ALS on motor neurons and central nervous system (CNS) cells, recent studies have unveiled that ALS pathogenesis extends beyond CNS imbalances, encompassing dysregulation in other tissues such as skeletal muscle. Evidence from animal models and patients supports this broader perspective. Skeletal muscle, once considered solely as an effector organ, is now recognized as possessing significant secretory activity capable of influencing motor neuron survival. However, the precise cellular and molecular mechanisms underlying the detrimental effects observed in muscle and its associated structures in ALS remain poorly understood. Additionally, emerging data suggest that extracellular vesicles (EVs) may play a role in the establishment and function of the neuromuscular junction (NMJ) under both physiological and pathological conditions and in wasting and regeneration of skeletal muscles, particularly in neurodegenerative diseases like ALS. This review aims to explore the key findings about skeletal muscle involvement in ALS, shedding light on the potential underlying mechanisms and contributions of EVs and their possible application for the design of biosensors.

3 June 2024 in Genes
Verified
Journal Article
Open access
PDF file
Elisabetta CarataElisabetta Carata
Elisabetta Carata
MMMarco Muci
Marco Muci
SMStefania Mariano
Stefania Mariano
SGSimona Di Giulio
Simona Di Giulio
ANAnnamaria Nigro
Annamaria Nigro
EPElisa Panzarini
Elisa Panzarini
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease targeting the brain and spinal cord. Non-neuronal cells, including macrophages, may contribute to the disruption of motor neurons (MNs), neuromuscular junction dismantling and clinical signs of ALS. Understanding the modality and the effect of MNs–macrophage communication is pivotal. Here, we focus on extracellular vesicle (EVS)-mediated communication and, in particular, we analyze the response of macrophages. NSC-34 cells transfected with mutant SOD1 (G93A, A4V, G85R, G37R) and differentiated towards MN-like cells, and Raw 264.7 macrophages are the cellular models of the study. mSOD1 NSC-34 cells release a high number of vesicles, both large-lEVs (300 nm diameter) and small-sEVs (90 nm diameter), containing inflammation-modulating molecules, and are efficiently taken up by macrophages. RT-PCR analysis of inflammation mediators demonstrated that the conditioned medium of mSOD1 NSC-34 cells polarizes Raw 264.7 macrophages towards both pro-inflammatory and anti-inflammatory phenotypes. sEVs act on macrophages in a time-dependent manner: an anti-inflammatory response mediated by TGFβ firstly starts (12 h); successively, the response shifts towards a pro-inflammation IL-1β-mediated (48 h). The response of macrophages is strictly dependent on the SOD1 mutation type. The results suggest that EVs impact physiological and behavioral macrophage processes and are of potential relevance to MN degeneration.